Efficacy, safety, and pharmacokinetics by BMI category in Phase 3/3b cabotegravir + rilpivirine long-acting trials

Cabotegravir + rilpivirine (CAB + RPV) is a guideline-recommended long-acting (LA) injectable regimen for the maintenance of HIV-1 virologic suppression. This post hoc analysis summarizes CAB + RPV LA results by baseline body mass index (BMI) category among Phase 3/3b trial participants. Data from C...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The Journal of infectious diseases 2023-12
Hauptverfasser:	Elliot, Emilie, Polli, Joseph W, Patel, Parul, Garside, Louise, Grove, Richard, Barnett, Vince, Roberts, Jeremy, Byrapuneni, Sri, Crauwels, Herta, Ford, Susan L, Van Solingen-Ristea, Rodica, Birmingham, Eileen, D'Amico, Ronald, Baugh, Bryan, van Wyk, Jean
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!